

CORTEX PHARMACEUTICALS INC/DE/  
Form SC 13G  
June 19, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13G**

Under the Securities Exchange Act of 1934

(Amendment No. )

**CORTEX PHARMACEUTICALS, INC.**

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

220524300

(CUSIP Number)

June 19, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13G

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 220524300

Page 2 of 9

1 Names of reporting persons

Origin Ventures II, L.P. (20 - 1849450)

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

Delaware

5 Sole voting power

Number of

shares 24,200,507 (1)  
6 Shared voting power

beneficially

owned by

each None  
7 Sole dispositive power

reporting

person 24,200,507 (1)  
8 Shared dispositive power  
with:

None

9 Aggregate amount beneficially owned by each reporting person

24,200,507 shares of Common Stock (1)

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

16.8% (2)

12 Type of reporting person (see instructions)

PN

- (1) Origin Ventures II, L.P. ( OVII ) has sole voting and dispositive control over 24,200,507 shares of common stock ( Common Stock ) of Cortex Pharmaceuticals, Inc. (the Issuer ), except that Origin Ventures II Management, LLC ( OVIIM ), the general partner of OVII, and Bruce N. Barron ( Barron ) and Steven N. Miller ( Miller ), managing directors of OVIIM, may be deemed to share the right to direct the voting and dispositive control over such stock.
- (2) This percentage is calculated based upon 144,041,558 shares of the Issuer s Common Stock issued and outstanding as of August 13, 2012, as disclosed in the Quarterly Report on Form 10-Q of the Issuer for the quarter ended June 30, 2012.

CUSIP No. 220524300

Page 3 of 9

1 Names of reporting persons

Origin Ventures II Management, LLC

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

Delaware

5 Sole voting power

Number of

shares 0  
6 Shared voting power

beneficially

owned by 24,200,507 (3)  
each 7 Sole dispositive power

reporting

person 0  
8 Shared dispositive power  
with:

24,200,507 (3)

9 Aggregate amount beneficially owned by each reporting person

24,200,507 shares of Common Stock(3)

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

16.8% (2)

12 Type of reporting person (see instructions)

CO

(3) OVIIM shares voting and dispositive control over the 24,200,507 shares of Common Stock beneficially owned by OVII.

3 of 9 Pages

CUSIP No. 220524300

Page 4 of 9

1 Names of reporting persons

**Bruce N. Barron**

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

U.S.A.

5 Sole voting power

Number of

0

shares 6 Shared voting power

beneficially

owned by

24,200,507 (4)

each 7 Sole dispositive power

reporting

person

0

8 Shared dispositive power

with:

24,200,507 (4)

9 Aggregate amount beneficially owned by each reporting person

24,200,507 shares of Common Stock (4)

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

16.8% (2)

12 Type of reporting person (see instructions)

IN

(4) Barron shares voting and dispositive control over the 24,200,507 shares of Common Stock beneficially owned by OVII.

4 of 9 Pages



CUSIP No. 220524300

Page 5 of 9

1 Names of reporting persons

Steven N. Miller

2 Check the appropriate box if a member of a group (see instructions)

(a)  (b)

3 SEC use only

4 Citizenship or place of organization

U.S.A.

5 Sole voting power

Number of

0

shares 6 Shared voting power

beneficially

owned by

24,200,507 (5)

each 7 Sole dispositive power

reporting

person

0

8 Shared dispositive power

with:

24,200,507 (5)

9 Aggregate amount beneficially owned by each reporting person

24,200,507 shares of Common Stock (5)

10 Check box if the aggregate amount in Row (9) excludes certain shares (see instructions)

11 Percent of class represented by amount in Row (9)

16.8% (2)

12 Type of reporting person (see instructions)

IN

(5) Miller shares voting and dispositive control over the 24,200,507 shares of Common Stock beneficially owned by OVII.

5 of 9 Pages

**Preliminary Statement:**

This Schedule 13G supplements and replaces, with respect to the reporting Persons defined herein, the Schedule 13D filed with the Securities and Exchange Commission ( SEC ) on March 22, 2013 by Aurora Capital LLC, Aurora Capital Corp., T Morgen Capital LLC, Morgen Krisch, Linda Lippa, Arnold S. Lippa, Jeff E. Margolis, Samyang Optics Co. Ltd., Origin Ventures II, L.P., Origin Ventures II Management, LLC, Bruce N. Barron, Steven N. Miller, David W. Carley, Kenneth M. Cohen, Peter Letendre and Steven Chizzik (collectively, the 13D Group ) relating to shares of Common Stock of Cortex Pharmaceuticals, Inc. (the Issuer ). The members of the 13D Group have determined that they no longer hold any shares of the Issuer with any purpose, or with the effect of, changing or influencing control of the Issuer or in connection with any transaction having that purpose of effect. In accordance with the Rule 13d-1(h) the Reporting Persons determined to again report their beneficial ownership of shares of Common Stock of the Issuer on Schedule 13G.

**Item 1.**

(a) Name of Issuer:

Cortex Pharmaceuticals, Inc. (the Issuer )

(b) Address of Issuer's Principal Executive Offices:

7700 Irvine Center Drive

Suite 750

Irvine, California 92618

**Item 2.**

(a) Name of Persons Filing:

(1) Origin Ventures II, L.P. ( OVII );

(2) Origin Ventures II Management, LLC ( OVIIM );

(3) Bruce N. Barron ( Barron ); and

(2) Steven N. Miller ( Miller and, collectively with OVII, OVIIM and Barron, the Reporting Persons )

(b) Address of Principal Business Office(s):

1033 Skokie Blvd., Suite 430

Northbrook, Illinois 60062

(c) Citizenship:

(1) Delaware

(2) Delaware

(3) United States of America

(4) United States of America

(d) Title of Class of Securities:

Common Stock, par value \$0.001 per share (the Common Stock )

(e) CUSIP Number:

220524300

**Item 3.**

6 of 9 Pages

13G

CUSIP No. 220524300

Page 7 of 9

Not applicable.

**Item 4. Ownership**

(a) Amount beneficially owned:

As of the date of this statement, OVII beneficially owned 24,200,507 shares of Common Stock of the Issuer and OVIIM, as the general partner of OVII, and Barron and Miller, as the managing directors of OVIIM, may be deemed to beneficially own 24,200,507 shares of Common Stock of the Issuer held by OVII.

(b) Percent of class:

16.8%

(c) Number of shares as to which the person has:

The information in Items 5 through 9 on the cover pages of this statement is hereby incorporated by reference.

**Item 5. Ownership of Five Percent or Less of a Class.**

As further provided in a First Amendment to Schedule 13D being filed by the 13D Group referred to in the Preliminary Statement to this Schedule 13G, this Schedule 13G is filed in connection with the dissolution of a group.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

## Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13G

As further provided in a First Amendment to Schedule 13D being filed by the 13D Group referred to in the Preliminary Statement to this Schedule 13G, this Schedule 13G is filed in connection with the dissolution of a group.

### **Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

7 of 9 Pages

13G

CUSIP No. 220524300

Page 8 of 9

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: June 19, 2013

ORIGIN VENTURES II, L.P.

By: Origin Ventures II Management, LLC,  
its General Partner

By: /s/ Bruce N. Barron

Name: Bruce N. Barron

Title: Managing Director

ORIGIN VENTURES II MANAGEMENT, LLC

By: /s/ Bruce N. Barron

Name: Bruce N. Barron

Title: Managing Director

/s/ Bruce N. Barron

Bruce N. Barron

/s/ Steven N. Miller

Steven N. Miller

8 of 9 Pages

13G

CUSIP No. 220524300

Page 9 of 9

Exhibit A

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees that (i) this statement on Schedule 13G has been adopted and filed on behalf of each of them and (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G as to any of the undersigned upon such person giving written notice thereof to each of the other persons signatory hereto, at the principal office thereof.

Date: June 19, 2013

ORIGIN VENTURES II, L.P.

By: Origin Ventures II Management, LLC,  
its General Partner

By: /s/ Bruce N. Barron

Name: Bruce N. Barron

Title: Managing Director

ORIGIN VENTURES II MANAGEMENT, LLC

By: /s/ Bruce N. Barron

Name: Bruce N. Barron

Title: Managing Director

/s/ Bruce N. Barron

Bruce N. Barron

/s/ Steven N. Miller

Steven N. Miller

9 of 9 Pages